8-K: TuHURA Biosciences Appoints Dr. Craig Tendler to Board of Directors

TuHURA Biosciences appoints Dr. Craig L. Tendler, former Vice President at Johnson & Johnson Innovative Medicine, to its Board of Directors, effective March 10, 2025.

Summary

• TuHURA Biosciences has appointed Dr. Craig L. Tendler to its Board of Directors, effective March 10, 2025.
• Dr. Tendler previously served as Vice President at Johnson & Johnson Innovative Medicine Research & Development.
• During his tenure at Johnson & Johnson, Dr. Tendler oversaw 30 major drug approvals and 13 FDA breakthrough designations.
• TuHURA is a Phase 3 registration-stage immuno-oncology company.
• The company is preparing to initiate a Phase 3 trial of IFx-2.0 in the second quarter of 2025.
• TuHURA plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML, following the closing of the previously announced proposed merger with Kineta.

Sentiment

Score: 7

Explanation: The announcement is positive due to the addition of an experienced industry professional to the board, which is likely to benefit the company's strategic direction and drug development efforts. However, the forward-looking statements and inherent risks associated with clinical trials temper the overall sentiment.

Positives

• The appointment of Dr. Tendler brings significant expertise in oncology drug development to TuHURA's Board.
• Dr. Tendler's experience includes overseeing major oncology business development opportunities and achieving worldwide approvals for transformational treatments.
• TuHURA is advancing IFx-2.0 through a registrational Phase 3 clinical trial planned to begin in the second quarter of 2025.
• The company's pipeline includes novel therapeutics focused on overcoming resistance to cancer immunotherapy.
• Dr. Tendler's experience includes overseeing major oncology business development opportunities, culminating in the acquisition/co-development of practice-changing oncology products.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those set forth in the forward-looking statements.
• These risks are detailed in TuHURA's filings with the SEC.

Future Outlook

TuHURA is preparing to initiate a Phase 3 trial of IFx-2.0 in the second quarter of 2025 and plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML, following the closing of the previously announced proposed merger with Kineta.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA, stated that Dr. Tendler's experience will be a valuable asset as they advance IFx-2.0 through its Phase 3 clinical trial.
• James Manuso, Ph.D., Chairman of TuHURA's Board of Directors, noted that Dr. Tendler's track record will supplement the Board's expertise at a critical juncture in TuHURA's development programs.
• Dr. Tendler believes TuHURA has the potential to make a significant impact on the immuno-oncology treatment landscape.

Industry Context

The appointment of Dr. Tendler, with his extensive experience in oncology drug development and approvals, signals TuHURA's commitment to advancing its immuno-oncology pipeline and potentially competing with established players in the field.

Comparison to Industry Standards

• Dr. Tendler's previous role at Johnson & Johnson Innovative Medicine involved overseeing the development and approval of several major oncology drugs, including ZYTIGA, AKEEGA, ERLEADA, DARZALEX, CARVYKTI, TECVAYLI, TALVEY, IMBRUVICA, RYBREVANT, and BALVERSA.
• These drugs are considered industry standards in their respective indications, demonstrating Dr. Tendler's expertise in bringing successful oncology treatments to market.
• TuHURA's focus on overcoming resistance to cancer immunotherapy aligns with a growing trend in the industry to develop more effective and personalized cancer treatments.
• The planned Phase 3 trial of IFx-2.0 as an adjunctive therapy to Keytruda (pembrolizumab) is a direct comparison to the current standard of care for advanced or metastatic Merkel Cell Carcinoma.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Dr. Tendler positively, as it strengthens the company's leadership and increases the likelihood of successful drug development.
• Employees may benefit from Dr. Tendler's expertise and guidance.
• Patients may benefit from the development of new and effective cancer treatments.

Next Steps

• The Board expects to appoint Dr. Tendler to one or more Board committees at a later date.
• TuHURA intends to enter into an indemnification agreement with Dr. Tendler.
• TuHURA is preparing to initiate a Phase 3 trial of IFx-2.0 in the second quarter of 2025.
• TuHURA plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML, following the closing of the previously announced proposed merger with Kineta.

Key Dates